喜报： 2019年7月中旬，吉林省奇健生物技术有限公司产品之一的生长素（HGH）原料在美国DMF(美国药物主文件)备案获批，备案号033745

In early 2022, Jilin Provincial Food and Drug Administration announced our "Drug export license for anabolic agents and peptide hormones" on website, it means that Qijian has become an approved enterprise for export human growth hormone (HGH) API in Jilin Province. Moreover in April 2021 Qijian obtained the "Drug Production License" for product HGH which updated and issued by CFDA, and the quality of HGH products meet the US FDA and EU GMP standards. In the new year, we will continue to improve our management level and provide customers with better products. 注：出口准许证获批公示连接地址吉林省药品监督管理局核（换）发《药品生产许可证》公告（2022年第1期）公示连接地址药品生产许可查询地址

喜报： 2019年7月中旬，吉林省奇健生物技术有限公司产品之一的生长素（HGH）原料在美国DMF(美国药物主文件)备案获批，备案号033745

喜报： 2019年7月中旬，吉林省奇健生物技术有限公司产品之一的生长素（HGH）原料在美国DMF(美国药物主文件)备案获批，备案号033745

Welcome leaders of Jilin Provincial Department of Commerce to Qijian Bio-Pharmaceutical for investigation

In 2024，Jilin Qijian Bio-Pharmaceutical Co., Ltd will take part in the following worldwide professional exhibitions, welcome to visit us

API (Butylphthalein) R&D Site, Production Site Verification and GMP Compliance Inspection of Jilin Qijian Bio-Pharmaceutical Co.,Ltd successfully passed.

CPHI Worldwide will be held in Barcelona, Spain on October 24-26, 2023.Jilin Qijian Bio-Pharmaceutical Co.,Ltd will attend the exhibition, Booth No: 80Q19, welcome to visit us.

Great News! Qijian has obtained the human growth hormone (HGH) API export license signed and approved by the Food and Drug Administration。

Jilin Qijian Bio-Pharmaceutical Co., Ltd. participated in the 2023CPHI Southeast Asia Exhibition